Because IBC is defined by the presence of tumor emboli within dermal lymphatic vessels and as it was recently shown that vessels inflammation could be regulated by beta-catenin-independent signaling pathway involving WNT5A and TNF alpha signaling [15], IBC specificity could be linked to WNT/TCF4/MYC pathway activation in inflammatory lymphatic vessels. This evidence concerns the gene CTNNB1 and inflammatory breast carcinoma.